Construction of a room-temperature phosphorescent quantum dot probe and quantitative detection of thyroxine and carbamazepine

In this paper, a new quantitative detection system for thyroxine (T-4) and carbamazepine (CBZ) was constructed. A mixture of MPA-capped Mn and ZnS quantum dots (MPA-Mn:ZnS QDs) exhibiting roomtemperature phosphorescence (RTP) was prepared, which serves as the detection signal. The hexadecyltrimethylammonium bromide/ MPA-Mn:ZnS QDs (CTAB/QD) compound binds T-4 to produce a CTAB/QDs&T-4 complex, which results in phosphorescent quenching of the quantum dots. By adding CBZ to CTAB/QDs&T-4, the phosphorescent quenching remains, allowing the quantitative detection of T-4 and CBZ. Under the best experimental conditions, the linear relationship of QDs/CTAB-T-4 is T-4 Delta RTP=0.4137C(T4)+0.1034, the correlation coefficient is R-2=0.999, the detection limit is 1.95 nmol/L, and the detection range is 4.85 nmol/L to 1.59 mu mol/L; the linear relationship of CTAB/QDs&T-4-CBZ is CBZ Delta RTP=0.4178x+0.112, the correlation coefficient is R-2 =0.995, the detection limit is 3.43 nmol/L and the detection range is 7.9 nmol/L to 1.555 mu mol/L. This method has many advantages, such as antiinterference (which can overcome the autofluorescence interference of biological samples), nontoxicity, sensitivity, simple operation and low cost, and can be applied to the quantitative detection of T-4 and CBZ in human serum samples. (C) 2020 Elsevier B.V. All rights reserved.

Automated summary

A new quantitative detection system for thyroxine and carbamazepine was constructed using quantum dots and room-temperature phosphorescence. This method has advantages such as anti-interference, nontoxicity, high sensitivity, simplicity, and low cost, making it suitable for the quantitative detection of thyroxine and carbamazepine in human serum samples.